Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Microbix Biosystms ( (TSE:MBX) ) has shared an update.
Microbix Biosystems is expanding its capabilities to produce recombinant antigens using synthetic biology, aiming to grow its market share in the immunoassay sector. This strategic move involves a modest investment and aims to offer a broader range of antigens at different price points, enhancing its value proposition to test makers and strengthening its supply chain.
More about Microbix Biosystms
Microbix Biosystems Inc. is a life sciences company that has been a leading producer of purified and inactivated antigens from native bacterial and viral organisms for over three decades. It supplies critical biological ingredients to more than 100 international manufacturers of immunoassays, which are diagnostic tests used to determine exposure to or immunity from pathogens.
YTD Price Performance: 7.50%
Average Trading Volume: 111,374
Technical Sentiment Consensus Rating: Sell
Current Market Cap: C$56.5M
Find detailed analytics on MBX stock on TipRanks’ Stock Analysis page.
